Imodium a-d and Adcirca drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Imodium a-d (loperamide hydrochloride) and Adcirca (tadalafil). Common drug interactions include flushing among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Imodium a-d and Adcirca. It is created by eHealthMe based on reports of 39 people who take the same drugs from the FDA, and is updated regularly.

What is Imodium a-d?

Imodium a-d has active ingredients of loperamide hydrochloride. It is often used in diarrhea. eHealthMe is studying from 8,944 Imodium a-d users. Check the latest studies of Imodium a-d.

What is Adcirca?

Adcirca has active ingredients of tadalafil. It is often used in pulmonary hypertension. eHealthMe is studying from 54,957 Adcirca users. Check the latest studies of Adcirca.



On Jul, 09, 2026

39 people who take Imodium a-d and Adcirca together, and have interactions are studied.

Imodium a-d and Adcirca drug interactions.

What are the common drug interactions of Imodium A-D and Adcirca, by gender? *:

female:

  1. Flushing (the warm, red condition of human skin)
  2. Swelling
  3. Catheter site discharge
  4. Catheter site erythema (redness of skin at catheter site)
  5. Catheter site infection (infection at the site of insertion)
  6. Culture wound positive
  7. Device dislocation
  8. Device related infection
  9. Headache (pain in head)
  10. Musculoskeletal discomfort (discomfort in the body's muscles, joints, tendons, ligaments and nerves)

male:

  1. Death
  2. Dyspnoea (difficult or laboured respiration)
  3. Headache (pain in head)
  4. Movement disorder (neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness)
  5. Oedema peripheral (superficial swelling)
  6. Oxygen saturation decreased
  7. Temperature intolerance (inability to go in temperature)

What are the common drug interactions of Imodium A-D and Adcirca, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Infusion site haemorrhage (bleeding from infusion site)
  2. Infusion site pain
  3. Infusion site reaction
  4. Infusion site swelling
  5. Insomnia (sleeplessness)
  6. Oedema peripheral (superficial swelling)
  7. Platelet count decreased
  8. Productive cough
  9. Dyspnoea (difficult or laboured respiration)
  10. Catheter site discharge

40-49:

  1. Abdominal pain
  2. Anticoagulation drug level below therapeutic
  3. Cellulitis (infection under the skin)
  4. Chills (felling of cold)
  5. Decreased appetite
  6. Drug abuse
  7. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
  8. Injection site erythema (redness at injection site)
  9. Injection site pain
  10. Movement disorder (neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness)

50-59:

  1. Swelling
  2. Abdominal pain upper
  3. Nausea (feeling of having an urge to vomit)
  4. Anaemia (lack of blood)
  5. Fatigue (feeling of tiredness)
  6. Blood calcium increased
  7. Chest pain
  8. Dyspnoea (difficult or laboured respiration)
  9. Fluid retention (an abnormal accumulation of fluid in the blood)
  10. Flushing (the warm, red condition of human skin)

60+:

  1. Headache (pain in head)
  2. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  3. Vomiting
  4. Cystitis (inflammation of the wall of the bladder)
  5. Urosepsis (secondary infection that occurs when a urinary tract infection spreads to the bloodstream)
  6. Anaemia (lack of blood)
  7. Arteriosclerosis coronary artery (thickening and hardening of arteries- coronary artery)
  8. Arthralgia (joint pain)
  9. Asthenia (weakness)
  10. Coronary artery occlusion (complete obstruction of blood flow in a coronary artery)

What are the existing conditions these people have? *

  1. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 32 people, 82.05%
  2. Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 2 people, 5.13%

* Approximation only. Some reports may have incomplete information.

Do you take Imodium a-d and Adcirca?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Imodium a-d and Adcirca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Imodium a-d:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Adcirca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Imodium a-d and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Adcirca and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on loperamide hydrochloride and tadalafil (the active ingredients of Imodium a-d and Adcirca, respectively), and Imodium a-d and Adcirca (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: